Affiliations: [a] Shenzhen Second People's Hospital, Clinical Medicine College of Anhui Medical University, Shenzhen, Guangdong, China | [b] Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Shenzhen, Guangdong, China | [c] Shantou University Medical College, Shantou, Guangdong, China
Correspondence:
[*]
Corresponding authors: Hongbing Mei and Yuchen Liu, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Shenzhen 518035, Guangdong, China. E-mail:hbmei68@163.com,liuyuchenmdcg@163.com
Note: [1] Equal contributors.
Abstract: OBJECTIVE: In this study, we examined the relationships between the
expression level of long non-coding RNA MIR31HG in bladder cancer and the
clinical characteristics. METHODS: A total of 55 tissue samples from patients with bladder
cancer were collected, and the lncRNA MIR31HG levels in cancer, paired
non-cancer tissues and BC cell lines were detected by real-time quantitative
RT-PCR (qRT-PCR). The relationships between MIR31HG level and the clinical
characteristics were evaluated. RESULTS: MIR31HG expression was remarkably decreased in bladder
cancer tissues compared with adjacent noncancerous tissues (P < 0.05).
MIR31HG expression was also significantly down-regulated in four bladder
cancer cell lines (P < 0.001). Clinicopathologic analysis revealed that
MIR31HG expression was negatively associated with TNM stage (P = 0.010), but
not with other clinicopathological characteristics. CONCLUSIONS: These findings revealed that MIR31HG may function as a
cancer-suppressor gene to participate in the bladder cancer carcinogenesis
and development.
